When we think about where AI can help, it’s about reducing administrative burden. Tools like Smart Draft help streamline ...
In today’s ACT Brief, we look at efforts to address sex-based evidence gaps in Parkinson’s disease research, why ...
Unpack why persistent communication breakdowns between sponsors, CROs, and sites undermine startup efficiency—and how ...
Pharma is understandably risk-averse, and many companies remain in pilot mode, running small experiments that never scale.
Examine the strategies community research sites can use to secure trial opportunities, from adopting AI-enabled workflows to ...
Mallon: The survey does highlight that principally prolonged contract and budget negotiations are probably the top barriers ...
In today’s ACT Brief, we examine how community research sites can stay competitive under rising efficiency pressures, why ...
In today’s ACT Brief, we look at how community research sites can stay competitive under efficiency pressure, why 2026 is ...
ACT Brief: Moving Beyond AI Pilots, FDA Advances Bayesian Trials, and Sites Strained by Trial Design
In today’s ACT Brief, we examine what will separate sponsors that scale AI beyond pilots in 2026, break down the FDA’s new ...
The clinical trial ecosystem is entering a phase of consolidation and reinvention driven by the collapse of boundaries between functions, data, and even companies themselves.
Unpack how rising competition for the same high-profile sites is slowing startup and enrollment—and what sponsors must change ...
Identifying copyright holders and response times are major challenges in COA licensing, causing delays in clinical trials. Clear documentation of copyright ownership and standardized response times ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback